AJOVista LLC Takes Position in Quanterix Co. (NASDAQ:QTRX)

AJOVista LLC bought a new stake in Quanterix Co. (NASDAQ:QTRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,971 shares of the company’s stock, valued at approximately $81,000.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC raised its stake in shares of Quanterix by 150.2% in the third quarter. SG Americas Securities LLC now owns 14,235 shares of the company’s stock valued at $386,000 after purchasing an additional 8,546 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in Quanterix during the third quarter valued at approximately $67,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Quanterix by 56.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,683 shares of the company’s stock valued at $209,000 after purchasing an additional 2,775 shares during the period. Emerald Advisers LLC acquired a new position in shares of Quanterix in the 3rd quarter worth approximately $10,462,000. Finally, Emerald Mutual Fund Advisers Trust lifted its position in shares of Quanterix by 353.4% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 313,044 shares of the company’s stock worth $8,496,000 after buying an additional 243,994 shares during the period. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Price Performance

Shares of QTRX stock traded up $0.10 during trading hours on Friday, reaching $17.02. 367,415 shares of the company were exchanged, compared to its average volume of 397,240. The stock’s fifty day moving average is $21.81 and its two-hundred day moving average is $23.15. Quanterix Co. has a fifty-two week low of $15.32 and a fifty-two week high of $29.70.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). The firm had revenue of $31.55 million for the quarter, compared to analyst estimates of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. Sell-side analysts forecast that Quanterix Co. will post -1.04 EPS for the current fiscal year.

Insider Activity

In other Quanterix news, Director Laurie J. Olson sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the transaction, the director now directly owns 15,238 shares of the company’s stock, valued at $371,045.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 6.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on QTRX. Canaccord Genuity Group cut their price objective on Quanterix from $32.00 to $25.00 and set a “buy” rating for the company in a report on Monday, April 29th. Scotiabank upped their price objective on shares of Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 4th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Quanterix has an average rating of “Buy” and an average price target of $30.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.